Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Parkinson's pump study tracks Real-Life symptom control

NCT ID NCT07219927

Symptom relief Sponsor: Supernus Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 120 people with Parkinson's disease who are using a continuous apomorphine infusion pump (ONAPGO™) to see how it works in real-world settings. Researchers will track how long it takes to find the right dose, any changes to other Parkinson's medications, and how patients feel their overall health has changed. The goal is to understand the practical benefits and challenges of this treatment outside of a controlled clinic environment.

Why investors are watching

Supernus Pharmaceuticals is running a phase 4 observational study of its Parkinson's disease drug ONAPGO, a continuous apomorphine infusion, in 120 real-world US patients. For a small-cap company, this readout matters because it tests how the drug performs outside controlled clinical settings, which can shape how doctors and patients view its practical value.

If it works: A positive result could strengthen the drug's reputation among physicians and support broader adoption in routine care. It may also provide the company with real-world evidence to discuss with payers and regulators.

If it fails: A negative or unclear result could raise doubts about the drug's real-world usefulness and slow its commercial uptake. Observational studies can also face delays or recruitment problems, which would push back any meaningful readout.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants are eligible for participation in this study after they have received a prescription for Onapgo

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participant has received a prescription for ONAPGO™ according to the standard of care. Participant has opted into receiving support services from the Clinical Nurse Navigator (CNN), a registered nurse specially trained to work with persons with Parkinson's disease, as noted on the Prescription Enrollment Form. The HCP/Investigator determines the participant is an appropriate study participant. Participant is able and willing to provide informed consent (or informed assent form \[IAF\], as applicable) and signs the consent form on the Enrollment Day. Exclusion Criteria: Did not receive a prescription for ONAPGO™. Prescribed ONAPGO™, but the HCP/Investigator determines the participant should not participate in this observational study. Concomitant use of ONAPGO™ with 5-HT3 antagonists, including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) or alosetron. Known hypersensitivity to apomorphine or to excipients of ONAPGO™, including sulfite (e.g., sodium metabisulfite).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Parkinson's Disease & Movement Disorders Center of Boca Raton

    RECRUITING

    Boca Raton, Florida, 33486, United States

  • Parkinson's Disease and Movement Disorders Center - Long Island

    RECRUITING

    Commack, New York, 11725, United States

  • Parkinson's Disease and Movement Disorders Center - Orange County (North)

    RECRUITING

    Irvine, California, 92618, United States

  • Parkinson's Disease and Movement Disorders Center - Orange County (South)

    RECRUITING

    Aliso Viejo, California, 92656, United States

  • Parkinson's Research Centers of America - Palo Alto

    RECRUITING

    Palo Alto, California, 94301, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.